ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Metabolism
Volume 48, Issue 4, April 1999, Pages 448-454
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Purchase PDF (5691 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/S0026-0495(99)90102-6    How to Cite or Link Using DOI (Opens New Window)
Copyright © 1999 Published by Elsevier Inc.

Differences in amyloid deposition in islets of transgenic mice expressing human islet amyloid polypeptide versus human islets implanted into nude mice*1

Gunilla WestermarkCorresponding Author Contact Information, a, b, c, d, e, Corresponding Author Contact Information, Per Westermarkb, c, d, e, a, Decio L. Eizirikb, c, d, e, a, Claes Hellerströmb, c, d, e, a, Niles Foxb, c, d, e, a, Donald F. Steinerb, c, d, e, a and Arne Anderssonb, c, d, e, a

a Divisions of Molecular and Immunological Pathology and Cell Biology, Linköping University, Linköping, Sweden b Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden c Department of Metabolism and Endocrinology, Diabetes Research Center, Vrije Universiteit Brussels and b-cell Transplant, Brussels, Belgium d Lilly Research Laboratories, Indianapolis, IN, USA e Department of Biochemistry and Molecular Biology and Howard Hughes Medical Institute, University of Chicago, Chicago, IL, USA

Received 17 March 1998; 
accepted 30 November 1998. 
Available online 31 August 2004.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

Islet amyloid polypeptide (IAPP)-derived amyloid is frequently deposited in the islets of Langerhans in patients with chronic non-insulin-dependent diabetes mellitus (NIDDM). When human islets were implanted under the renal capsule in nude mice, amyloid occurred in 73% of the grafts within 2 weeks. In this study, we compare the deposition of amyloid in islets from a transgenic mouse strain expressing human IAPP (hIAPP) and in normal human islets after implantation in nude mice. The implantations were performed as follows: (1) nondiabetic recipients were given islets from transgenic mice alone, (2) human islets were implanted in the upper pole of the kidney and islets from transgenic mice were implanted in the lower pole of the kidney, (3) grafts containing a mixture of human and transgenic islets were implanted, and (4) transgenic islets and islets from nontransgenic littermates were implanted in therapeutic numbers into recipients made diabetic by a single injection of alloxan prior to implantation. The implants were removed after various periods from 4 days to 8 weeks. The implants were either fixed in Formalin, stained for amyloid, and viewed in polarized light, or processed for immunoelectron microscopy and studied after immunolabeling with specific antibodies against IAPP. We found that the course of amyloid deposition differed significantly between human islets and hIAPP-expressing mouse islets. In human islets, amyloid was mainly deposited intracellularly and only small amounts of amyloid were found extracellularly. In contrast, in islets from transgenic mice, amyloid was exclusively deposited extracellularly and deposition in this site was preceded by an aggregation of immunoreactive material along the basement membrane. These findings point to separate mechanisms for amyloid formation in these two models.

Article Outline

• References

Metabolism
Volume 48, Issue 4, April 1999, Pages 448-454
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.